The Molecular, Biochemical and Human Pharmacology of Thromboxane A2 in Renal Disease

FitzGerald, Garret A.; Murray, Rosemary; Price, Peter M.; Catella, Francesca

doi:10.1007/978-1-4684-5700-1_14

Cited by 5 publications

(1 citation statement)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It deteriorates more in vascular and interstitial nephropathies than in glomerular diseases, because glomeruli are only responsible for 10% of intraparenchimal flow resistances, whose control is mainly under the action of efferent and afferent arteries [25,26] . The increase of total peripheral resistance of the kidney, determined by release of vasoconstrictive substances and remodeling of the microcirculation in course of vascular and interstitial nephropathies could explain the higher RI found in these diseases [27] .…”

Section: Discussionmentioning

confidence: 99%

N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis

et al. 2009

View full text Add to dashboard Cite

Aim: To evaluate resistance index (RI) changes in renal artery after N-acetylcysteine infusion in patients with systemic sclerosis. Methods:In an open-label study 40 patients with systemic sclerosis (SSc) were treated with N-acetylcysteine (NAC) iv infusion over 5 consecutive hours, at a dose of 0.015 g·kg -1 ·h -1. Renal haemodynamic effects were evaluated by color Doppler examination before and after NAC infusion. Results: NAC infusion significantly reduced RI in a group of sclerodermic patients with early/active capillaroscopic pattern, modified Rodnan Total Skin Score (mRTSS) <14 and mild-moderate score to the vascular domain of Medsger Scleroderma Disease Severity Scale (DSS). RI increased after NAC infusion in patients with late capillaroscopic pattern, mTRSS>14 and severe-end stage score to the vascular domain of DSS. In patients with reduction of RI after NAC infusion, diffusion capacity for carbon monoxide mean value was significantly higher than in those patients with an increase of RI. No significant differences in renal blood flow were found between patients with different subsets of SSc. Conclusion: In patients with low disease severity NAC ameliorates vascular renal function.

show abstract

Section: Discussionmentioning

confidence: 99%

N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis

et al. 2009

View full text Add to dashboard Cite

show abstract

Thromboxane A₂ receptor antagonists

Hall

1991

Medicinal Research Reviews

View full text Add to dashboard Cite

Metabolism of 5,6-epoxyeicosatrienoic acid by the human platelet. Formation of novel thromboxane analogs.

Balazy

1991

Journal of Biological Chemistry

View full text Add to dashboard Cite

The Molecular, Biochemical and Human Pharmacology of Thromboxane A2 in Renal Disease

Cited by 5 publications

References 116 publications

N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis

N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis

Thromboxane A₂ receptor antagonists

Metabolism of 5,6-epoxyeicosatrienoic acid by the human platelet. Formation of novel thromboxane analogs.

Contact Info

Product

Resources

About

The Molecular, Biochemical and Human Pharmacology of Thromboxane A2 in Renal Disease

Cited by 5 publications

References 116 publications

N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis

N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis

Thromboxane A2 receptor antagonists

Metabolism of 5,6-epoxyeicosatrienoic acid by the human platelet. Formation of novel thromboxane analogs.

Contact Info

Product

Resources

About

Thromboxane A₂ receptor antagonists